Health
Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas – News-Medical.Net
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up, published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory…
-
Noosa News23 hours agoQueensland man sentenced to four years imprisonment after string of terror offences
-
Noosa News23 hours agoBali traveller sparks urgent measles alert across Queensland
-
Business23 hours agoThe best ASX ETFs for compounding wealth until 2040
-
Noosa News22 hours agoMeasles alert issued south of Brisbane after traveller tests positive